South Korea Biologics Contract Development And Manufacturing Organization (cdmo) Market Size & Outlook
Related Markets
South Korea biologics contract development and manufacturing organization (cdmo) market highlights
- The South Korea biologics contract development and manufacturing organization (cdmo) market generated a revenue of USD 274.6 million in 2025 and is expected to reach USD 488.3 million by 2033.
- The South Korea market is expected to grow at a CAGR of 7.7% from 2026 to 2033.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating product in 2025.
- Nucleic Acid Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Biologics contract development and manufacturing organization (cdmo) market data book summary
| Market revenue in 2025 | USD 274.6 million |
| Market revenue in 2033 | USD 488.3 million |
| Growth rate | 7.7% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Nucleic Acid Therapeutics |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies (mAbs), Recombinant Proteins & Enzymes, Vaccines, Cell & Gene Therapies, Nucleic Acid Therapeutics, Other Product |
| Key market players worldwide | Lonza, Catalent Pharma Solutions, Samsung BioLogics, WuXi Biologics., Thermo Fisher Scientific Inc, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Boehringer Ingelheim, Rentschler Biopharma SE, AGC Biologics, Charles River Laboratories International Inc., Siegfried Holding AG, Sandoz, GenScript, Vetter Pharma, IDT Biologika |
Other key industry trends
- In terms of revenue, South Korea accounted for 0.6% of the global biologics contract development and manufacturing organization (cdmo) market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China biologics contract development and manufacturing organization (cdmo) market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,944.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Contract Development And Manufacturing Organization (CDMO) Market Scope
Biologics Contract Development And Manufacturing Organization (CDMO) Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Sandoz | View profile | 10001+ | Holzkirchen, Bayern, Germany, Europe | https://www.sandoz.de |
| Fujifilm Diosynth Biotechnologies U.S.A., Inc. | View profile | - | - | - |
| Vetter Pharma | View profile | - | - | - |
| WuXi Biologics. | View profile | - | - | - |
| Lonza | View profile | - | - | - |
| GenScript | View profile | - | - | - |
| Charles River Laboratories International Inc. | View profile | - | - | - |
| Catalent Pharma Solutions | View profile | 5001-10000 | Somerset, New Jersey, United States, North America | http://www.catalent.com |
| IDT Biologika | View profile | 1001-5000 | Dessau, Sachsen-Anhalt, Germany, Europe | https://idt-biologika.de/ |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| AGC Biologics | View profile | 1001-5000 | Bothell, Washington, United States, North America | http://www.agcbio.com/ |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | https://www.rentschler-biopharma.com |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
South Korea biologics contract development and manufacturing organization (cdmo) market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development and manufacturing organization (cdmo) market will help companies and investors design strategic landscapes.
Monoclonal antibodies (mabs) was the largest segment with a revenue share of 44.1% in 2025. Horizon Databook has segmented the South Korea biologics contract development and manufacturing organization (cdmo) market based on monoclonal antibodies (mabs), recombinant proteins & enzymes, vaccines, cell & gene therapies, nucleic acid therapeutics, other product covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to South Korea biologics contract development and manufacturing organization (cdmo) market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Korea biologics contract development and manufacturing organization (cdmo) market databook
-
Our clientele includes a mix of biologics contract development and manufacturing organization (cdmo) market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea biologics contract development and manufacturing organization (cdmo) market , including forecasts for subscribers. This country databook contains high-level insights into South Korea biologics contract development and manufacturing organization (cdmo) market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
South Korea biologics contract development and manufacturing organization (cdmo) market size, by product, 2021-2033 (US$M)
South Korea Biologics Contract Development And Manufacturing Organization (CDMO) Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
